Growth Hormone Secretagogue (Peptide Combination)
Dragon Pharma Peptide Product
Dragon Pharma CJC 1295 No DAC/Ipamorelin is supplied as a lyophilized powder in a 2 mL vial and contains a combination of two peptides: CJC 1295 No DAC and Ipamorelin, each at a labeled strength of 5 mg. Product specifications, a batch-specific lab report, storage information, and available payment options are provided below.
Contains equal amounts (5 mg each) of CJC 1295 No DAC and Ipamorelin per vial.
Supplied as a freeze-dried powder requiring reconstitution with bacteriostatic water before use.
Packaged in a standard 2 mL peptide vial with a rubber stopper and aluminum seal.
A published lab report from November 2025 provides measured results for the identified batch.
| Product name | CJC 1295 No DAC 5 mg/Ipamorelin 5 mg |
|---|---|
| Active substances | CJC 1295 No DAC, Ipamorelin |
| Labeled strength | 5 mg CJC 1295 No DAC / 5 mg Ipamorelin |
| Total labeled content | 10 mg per vial |
| Container | 2 mL vial |
| Product form | Lyophilized powder |
| Manufacturer | Dragon Pharma |
The latest published report for batch #HDCI10, dated November 7, 2025, measured 5.93 mg of CJC 1295 No DAC and 4.96 mg of Ipamorelin against the stated 5 mg concentration for each peptide.
Open the Lab Reports tab to view the full report and check the batch number associated with the test.
Other peptide options from the same product line include Ipamorelin 5 mg as a single-peptide product, and CJC 1295 DAC 5 mg, which uses a modified version of the peptide with different release characteristics. These products differ in their active peptide composition and are not interchangeable.
Published Test Result
A published lab report for Dragon Pharma CJC 1295 No DAC/Ipamorelin is provided below with the test date, measured results and reported batch number. Each result can be compared directly with the product's labeled strength of 5 mg per peptide.
Science & Research
CJC 1295 No DAC and Ipamorelin are peptides that act on the growth hormone axis. This section provides a brief overview of what these peptides are and how they work at a basic level.
CJC 1295 No DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone. The "No DAC" designation indicates the peptide lacks the drug affinity complex found in the original CJC 1295, which affects its release profile.
Ipamorelin is a synthetic peptide that belongs to the growth hormone-releasing peptide (GHRP) class. It acts on the ghrelin receptor to stimulate growth hormone release. Compared with other GHRPs, it has a relatively low effect on appetite and cortisol levels in research settings.
Combining a GHRH analogue (CJC 1295 No DAC) with a GHRP (Ipamorelin) is a common research approach that uses two distinct pathways to promote growth hormone secretion. The combination may produce a different effect compared with either peptide used alone.
This product is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water or sterile water for injection before use. The addition of water converts the freeze-dried powder into a solution suitable for subcutaneous injection.
The reconstituted peptide solution should be stored as recommended on the product label. Peptide solutions are typically refrigerated and used within a specified timeframe after reconstitution to maintain integrity.
Peer-reviewed research on growth hormone secretagogues, including CJC-1295 and Ipamorelin, is available through the National Institutes of Health and other scientific databases. The following links provide general information on growth hormone-releasing peptides and their mechanisms of action.
Important Health Information
Peptide research compounds such as CJC 1295 No DAC and Ipamorelin have limited clinical safety data. The information below is derived from published preclinical research and general knowledge of the growth hormone axis and does not constitute medical advice.
CJC 1295 No DAC and Ipamorelin have not been extensively studied in humans. The available safety information comes primarily from preclinical research.
Peptides that stimulate growth hormone release have the potential to affect glucose metabolism, insulin sensitivity and fluid balance. These effects are not well characterized for this specific combination.
Subcutaneous injection carries risks including injection-site reactions, infection and improper technique. Sterile handling and correct reconstitution procedures are essential.
Compounds that affect the growth hormone axis may interact with other hormonal systems, including thyroid and adrenal function. The potential significance of these interactions is not fully understood.
Growth hormone-releasing peptides may have central nervous system effects in preclinical research, including effects on sleep and appetite. The clinical significance of these findings is unknown.
Peptide research compounds should not be used by individuals with known allergies or sensitivities to peptide compounds, or by those who are pregnant, nursing or have active malignancies.
Medical advice is particularly important for individuals with diabetes or glucose metabolism disorders, cardiovascular disease, cancer or a history of cancer, pituitary disorders, or those taking medications that affect hormone levels. Peptide compounds should not be used during pregnancy or breastfeeding.
The product should also be stored securely to prevent accidental access or use by children or other household members, particularly after reconstitution when it contains a liquid solution.
Growth hormone-releasing peptides, including CJC-1295 and Ipamorelin, are prohibited under anti-doping rules in tested sport at all times unless an applicable therapeutic-use exemption has been granted.
The current status and applicable rules can be checked through the World Anti-Doping Agency Prohibited List.
Common Product Questions
Quick answers about CJC 1295 No DAC/Ipamorelin specifications, the published lab report, storage, shipping, Bitcoin payment and general product information.
Dragon Pharma CJC 1295 No DAC/Ipamorelin is a lyophilized peptide product containing 5 mg of CJC 1295 No DAC and 5 mg of Ipamorelin per vial. It is supplied in a 2 mL vial for research purposes.
The main difference is the presence of the Drug Affinity Complex (DAC). CJC 1295 No DAC has a shorter duration of action compared with CJC 1295 DAC, which is modified to have a longer half-life. These are not the same product and should not be used interchangeably.
Each vial contains a labeled strength of 5 mg of CJC 1295 No DAC and 5 mg of Ipamorelin, for a total of 10 mg of peptide content per vial.
The product is supplied as a lyophilized powder in a 2 mL vial. It requires reconstitution with bacteriostatic water or sterile water for injection before use.
The published lab report dated November 7, 2025 for batch #HDCI10 measured 5.93 mg of CJC 1295 No DAC and 4.96 mg of Ipamorelin against the stated 5 mg labeled strength for each peptide.
No. Each report applies to the sample submitted for that specific test and the batch identified in the report. It does not independently verify the content or condition of every individual vial.
Store the lyophilized powder in its original packaging at room temperature or refrigerated, protected from excessive heat, moisture and direct light. Once reconstituted, peptide solutions typically require refrigeration and should be used within a limited timeframe. Always follow the specific storage directions printed on the product label.
Lyophilized peptide powders are generally stable at room temperature but should be protected from heat. After reconstitution, peptide solutions typically require refrigeration. Check the product label for specific storage instructions.
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4–5 business days after dispatch, while shipments from the International Warehouse typically take 15–20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy CJC 1295 No DAC/Ipamorelin with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
Growth hormone-releasing peptides, including CJC-1295 and Ipamorelin, are prohibited under anti-doping rules in tested sport unless an applicable therapeutic-use exemption has been granted. Current requirements should be checked against the relevant anti-doping rules before competition.
Additional research on these peptides is available through the National Institutes of Health and other scientific databases. Direct links to PubMed references are provided in the Science & Research section above.
Please log in to write CJC 1295 No DAC 5 mg/Ipamorelin 5 mg review.
Trade Name: TB 500/BPC 157
Compound: Thymosin Beta 4, Pentadecapeptide
Strength: 10 mg/vial
Container: 2 mL Vial
Manufacturer: Dragon Pharma
Lab Tested: View Result